TPD52L2 and breast cancer: In our study, TPD52L2 gene expression was also proven to be closely associated with the efficacy and outcome of radiation therapy, as breast cancer patients with low TPD52L2 levels had longer survival times after radiation therapy, as well as target therapy, than those with high TPD52L2 levels (Figures 3(e) and 3(f)).